

# Andrea Schietinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8925697/publications.pdf>

Version: 2024-02-01

29  
papers

5,647  
citations

394421

19  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

8952  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	22.7	345
2	An autoimmune stem-like CD8 T cell population drives type 1 diabetes. <i>Nature</i> , 2022, 602, 156-161.	27.8	85
3	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	64
4	Ketohexokinase-mediated fructose metabolism is lost in hepatocellular carcinoma and can be leveraged for metabolic imaging. <i>Science Advances</i> , 2022, 8, eabm7985.	10.3	9
5	Turbocharging the T Cell to Fight Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2334-2336.	27.0	3
6	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET. <i>Clinical Cancer Research</i> , 2021, 27, 1958-1966.	7.0	21
7	An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22
8	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
9	Ectopic activation of the miR-200c/EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. <i>Science Translational Medicine</i> , 2021, 13, eabg4328.	12.4	8
10	Exercise and immunometabolic regulation in cancer. <i>Nature Metabolism</i> , 2020, 2, 849-857.	11.9	25
11	Mite Burden and Immunophenotypic Response to <i>Demodex musculi</i> in Swiss Webster, BALB/c, C57BL/6, and NSG Mice. <i>Comparative Medicine</i> , 2020, 70, 336-348.	1.0	0
12	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
13	Defining T cell exhaustion™. <i>Nature Reviews Immunology</i> , 2019, 19, 665-674.	22.7	879
14	Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. <i>Current Opinion in Immunology</i> , 2019, 58, 98-103.	5.5	83
15	Rejection of immunogenic tumor clones is limited by clonal fraction. <i>ELife</i> , 2018, 7, .	6.0	88
16	Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. <i>Nature Medicine</i> , 2017, 23, 242-249.	30.7	179
17	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	27.8	643
18	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , 2016, 45, 389-401.	14.3	496

#	ARTICLE	IF	CITATIONS
19	Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease. <i>Blood</i> , 2016, 128, 653-653.	1.4	1
20	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. <i>Blood</i> , 2016, 128, 861-861.	1.4	0
21	Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance. <i>Trends in Immunology</i> , 2015, 36, 665-667.	6.8	2
22	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. <i>Trends in Immunology</i> , 2014, 35, 51-60.	6.8	513
23	Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. <i>OncImmunology</i> , 2013, 2, e26677.	4.6	47
24	Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State. <i>Science</i> , 2012, 335, 723-727.	12.6	149
25	Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4 <sup>+</sup> T cells. <i>Immunology</i> , 2010, 130, 494-503.	4.4	7
26	Bystander killing of cancer requires the cooperation of CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells during the effector phase. <i>Journal of Experimental Medicine</i> , 2010, 207, 2469-2477.	8.5	116
27	Specificity in cancer immunotherapy. <i>Seminars in Immunology</i> , 2008, 20, 276-285.	5.6	98
28	Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma. <i>Cancer Research</i> , 2008, 68, 1563-1571.	0.9	70
29	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 49-55.	8.5	348